Ligand Design

The term "indirect drug design" is another name for Ligand Design. It is dependent on knowledge of several novel ligand molecules that bind to the target protein molecule. In order to create a fresh explanation for each and every component involved for the interaction between the ligand and the target protein molecule, various designed compounds are utilised. These components should improve the ligand-protein interaction if they are present in a ligand. On the basis of the composite ligand, a target protein model is also created. Drug development based on ligands is dependent on knowledge of other compounds that bind to the biological target's active site with specific interest. These sorts of compounds are utilised to create a model that accurately captures the crucial structural characteristics of a lead molecule, which aids in binding process with the target molecule. Based on the knowledge of the molecules that bind, a model of the biologically active target is created. Utilizing this concept, new compounds are created that interact with the physiologically active target molecule. A link between the molecules' estimated characteristics and their empirically discovered biological activity is known as a quantitative structure activity relationship. To forecast the activity of the novel compounds, QSAR investigations are employed. Protein models are often created so that researchers may learn more and more about the various ligands and how they interact with the target protein. Protein molecules that function as enzymes are a key target for rational drug design. By converting less energy from the substrate molecule into the creation of the product, enzymes are the molecules that catalyse biochemical reactions.